Addex Therapeutics Ltd (ADXN), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological disorders, is set to release its official Q3 2024 financial results on November 22, 2024. Provisional reports suggest a significant decrease in net income compared to the prior quarter, influenced by one-time gains in Q2.
Is now the time to buy Addex Therapeutics? Access our full analysis report here, it’s free.
Expected Q3 Earnings Report of Addex Therapeutics Ltd:
Provisional results show a Q3 2024 net loss of CHF 1.5 million, a notable decline from the Q2 net profit of CHF 12.9 million. This change reflects the absence of non-recurring gains from the sale of part of Addex’s business to Neurosterix in Q2, which contributed CHF 14.0 million. While the nine-month net profit as of September 30, 2024, stands at CHF 8.3 million, this marks a modest decline from CHF 9.8 million reported at the six-month mark.
Addex anticipates quarterly losses moving forward. Its cash position as of September 30, 2024, was CHF 3.3 million, highlighting the financial challenges for the company as it continues to develop its therapeutic portfolio.
Stock Target Advisor’s Analysis on Addex Therapeutics Ltd:
Stock Target Advisor rates Addex Therapeutics Ltd as “Bearish,” with two positive signals counterbalanced by six negative indicators. Positive aspects include the stock’s undervaluation compared to book value and superior earnings growth over the past five years. However, concerns such as low market capitalization, high volatility, and negative cash flow, earnings, and free cash flow persist.
Discover detailed Analyst Ratings and projections for Addex Therapeutics Ltd to gain deeper insights into its market potential
The company’s stock price, recently trading at USD 7.38, reflects a 1.25% decline over the past week and a 3.06% decline over the past month but has seen a year-over-year gain of 31.79%. Analysts forecast a target price of USD 30 over the next 12 months, indicating potential upside despite current challenges.
Conclusion:
As Addex Therapeutics approaches the release of its finalized Q3 2024 financial results, investors face a mix of optimism about long-term growth prospects and caution stemming from recent financial volatility. With the company’s innovative focus in the biopharmaceutical sector, its ongoing challenges, and analyst predictions, the forthcoming webcast is expected to shed light on Addex’s strategies for overcoming hurdles and capitalizing on opportunities.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
